(Hypertension. 2000;35:337.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Department of Physiology, Medical College of Wisconsin, Milwaukee.
Correspondence to David L. Mattson, PhD, Department of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226. E-mail dmattson{at}mcw.edu
| Abstract |
|---|
|
|
|---|
Key Words: rats, Sprague-Dawley kidney nitric oxide synthase RNA
| Introduction |
|---|
|
|
|---|
Many biochemical and molecular studies have been performed to identify both mRNA and immunoreactive protein of neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) in renal vessels. The mRNA for nNOS has been localized in glomeruli and vasa recta12 ; nNOS protein has been identified in efferent arterioles13 ; eNOS mRNA has been identified in glomeruli, arcuate arteries, interlobular arteries, and afferent arterioles14 ; and eNOS protein has been identified in the endothelium of preglomerular and postglomerular vessels by immunohistochemical techniques.13 The mRNA encoding iNOS has also been found in arcuate and interlobular arteries and glomeruli by in situ hybridization and reverse transcription (RT)polymerase chain reaction (PCR) of microdissected segments.15 Despite these types of studies, however, there is little information available regarding NOS enzymatic activity in the individual segments of the renal vasculature. The present study was designed to examine total and calcium-independent NOS enzymatic activity in dissected vessels obtained from the Sprague-Dawley rat kidney and to identify the NOS isoforms present in each vessel segment by RT-PCR.
| Methods |
|---|
|
|
|---|
Microdissection of Renal Vessels
Microdissection was performed as described previously.12 16 17 Rats were anesthetized with pentobarbital sodium (50 mg/kg body wt IP), and the aorta below the left renal artery was isolated and cannulated. After ligating the aorta at a site between the origin of the left and right renal arteries, the left kidney was flushed with 10 mL ice-cold dissection solution containing (in mmol/L) NaCl 135, KCl 3, CaCl2 1.5, MgSO4 1, KH2PO4 2, glucose 5.5, and HEPES 10 (pH 7.4) and then perfused with 1 mL of 1.0-µm Blue Dyed Polybeads (Polyscience, Inc) for isolation of the arcuate artery, interlobular artery, afferent arteriole, and glomerulus or with 0.1-µm Blue Dyed Polybeads for isolation of the vasa recta. After perfusion, the kidney was removed and cut into 1- to 2-mm-thick sections containing the entire corticomedullary axis. The sections were incubated at 37°C for 30 minutes in digestion solution that was prepared by adding 2 mg/mL collagenase (CLS 2, Worthington) to the dissection solution with gentle shaking and bubbling with 100% O2. The slices were then rinsed twice with collagenase-free dissection solution and transferred into a Petri dish filled with ice-cold dissection solution containing 1% BSA. The Petri dish was then mounted on the cooling microscope stage and maintained at 4°C during dissection. Microdissection was performed under a LEICA M3Z stereomicroscope with dark-field illumination. The following segments were dissected: arcuate artery, interlobular artery, afferent arteriole, glomerulus, and vasa recta. The time period for dissection was limited to 1.5 hours.
NOS Enzyme Assay
The quantification of NOS enzymatic activity was performed as we have previously described.12 The dissected arcuate artery, interlobular artery, afferent arteriole, glomerulus, and vasa recta were incubated with 2 mmol/L CaCl2, 1 mmol/L NADPH, 25 µmol/L flavin adenine dinucleotide, 1.25 µg/mL calmodulin, 10 µmol/L tetrahydrobiopterin, and L-[3H]arginine (
300 000 cpm, specific activity 68 Ci/mmol) in 50 µL of 20 mmol/L HEPES buffer, pH 7.2, at 37°C for 2 hours. Calcium-independent activity was measured after the addition of 1.0 mmol/L EDTA and the elimination of calcium/calmodulin from the assay. The reaction mixture was centrifuged and separated into the supernatant and sediment. The L-arginine and converted L-citrulline in the supernatant were separated by isocratic reverse-phase high-performance liquid chromatography with a Supelco LC-18-DB column (mobile phase 11.5% methanol, 11.5% acetonitrile, 1% tetrahydrofuran, and 0.1 mol/L KH2PO4, pH 5.9). The amounts of L-[3H]arginine and converted L-[3H] citrulline were quantified by radiochemical detection (Packard). NOS activity was determined from the ratio of the total L-[3H]arginine converted to L-[3H]citrulline and the amount of total arginine in the reaction. The vessel sediment was washed once with dissection solution and then dissolved in Coomassie blue dye for the determination of total vessel protein. The total vessel length was not determined in these studies.
RNA Extraction and RT-PCR of NOS Isoforms
The extraction of RNA and RT-PCR identification of NOS isoforms in the dissected renal vessels was performed as we have previously described.12 16 17 The dissected kidney vessels or vessel pieces were washed and placed in individual tubes containing 500 µL TRIzol reagent (Life Technologies); after vortex mixing, chloroform was added to each tube (100 µL). The mixtures were centrifuged at 12 000g for 15 minutes, and the aqueous phase was removed. The RNA was precipitated with 250 µL isopropanol and washed with 500 µL of 75% ethanol. The resultant RNA was allowed to dry at room temperature and dissolved in 8 µL of RNase-free diethyl pyrocarbonate water.
A first-strand cDNA synthesis kit (Pharmacia Biotech) was used to synthesize cDNA by RT from RNA extracted from the individual vessels. As described by the manufacturer, 8 µ of total RNA was heated at 65°C for 10 minutes, rapidly chilled on ice, and then mixed with 7 µL of the reagents supplied with the kit. The reaction mixture contained 0.2 µg random hexadeoxynucleotides, 45 mmol/L Tris (pH 8.3), 68 mmol/L KCl, 15 mmol/L dithiothreitol, 9 mmol/L MgCl2, 0.08 mg/mL BSA, 1.8 mmol/L dNTPs, and 100 U Moloney murine leukemia virus reverse transcriptase. The reaction mixture was incubated at 37°C for 60 minutes and then heated to 65°C for 10 minutes to inactivate the reverse transcriptase and denature the cDNA hybrids.
The PCR reactions were performed in a total volume of 50 µL by use of a PCR Supermix kit (GIBCO-BRL) containing 22 mmol/L Tris-HCl (pH 8.4), 55 mmol/L KCl, 1.65 mmol/L MgCl2, 200 µmol/L dNTPs, 3 µL RT reaction mixture (1 µL for ß-actin), 22 U recombinant Taq DNA polymerase, and 40 pmol of the specific primer pairs for nNOS, eNOS, iNOS, or ß-actin. The reactions were thermocycled 35 times between 94°C (denaturation) for 1 minute, 56°C (annealing) for 1 minute, and 72°C (extension) for 1 minute. The reactions were extended for an additional 7 minutes at 72°C after the last cycle was completed. Negative control PCR reactions with a substitution of dissection solution for the RNA sample or total RNA without RT reaction were performed in parallel.
All nucleotide primers were purchased from Operon Technologies, Inc, as we have previously described.12 The primer pairs were chosen from the published cDNA sequences of rat nNOS,18 rat eNOS,15 rat iNOS,19 and human ß-actin. The primer sequence for nNOS corresponded to 5'-GGC ACT GGC ATC GCA CCC TT-3' (sense, base pairs 4096 to 4115) and 5'-CTT TGG CCT GTC CGG TTC CC-3' (antisense, base pairs 4308 to 4289); the final PCR product was 213 bp in size. The primers for eNOS corresponded to 5'-CTG CTG CCC GAG ATA TCT TC-3' (sense, base pairs 255 to 274) and 5'-CAG GTA CTG CAG TCC CTC CT-3' (antisense, base pairs 482 to 465); the final PCR product was 228 bp in size. The primers for iNOS corresponded to: 5'-AGC ATC ACC CCT GTG TTC CAC CC-3' (sense, base pairs 1592 to 1613) and 5'-TGG GGC AGT CTC CAT TGC CA-3' (antisense, base pairs 1979 to 1960); the final PCR product was 388 bp in size. Oligonucleotide primers for ß-actin (sense, 5'-AAC CGC GAG AAG ATG ACC CAG ATC ATG TTT-3'; antisense, 5'-AGC AGC CGT GGC CAT CTC TTG CTC GAA GTC-3') were used as positive controls in each on the basis of previous work by Briggs et al20 involving microdissected tubular and vascular segments. The PCR products were separated on a 1.5% agarose gel in 1x tris-borate EDTA electrophoresis buffer (10 V/cm gel length for 1 hour), stained with ethidium bromide (0.5 µg/mL), visualized under UV light, and photographed.
The RT-PCR products for nNOS, eNOS, and iNOS were ligated into pCR2.1 vector (Invitrogen), and the subsequent plasmid DNA was purified by use of ion-exchange columns (QIAGEN). To confirm the authenticity of the RT-PCR product, each insert was sequenced by ThermoSequenase with the use of the dideoxynucleotide chain termination reaction (Amersham). The samples were resolved on a DNA sequencer (model 725, Molecular Dynamics).
Statistical Methods
Data are presented as mean±SE. The significance of differences was evaluated by ANOVA and Student-Newman-Keuls post hoc tests. A confidence level of P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
RT-PCR Identification of NOS Isoforms in Renal Microvessels
After the measurement of total NOS enzymatic activity in different vascular segments, further studies were performed to identify the NOS isoforms present in each vessel. A representative ethidium bromidestained gel with RT-PCR products for nNOS, eNOS, iNOS, and ß-actin from RNA obtained from arcuate arteries, interlobular arteries, afferent arterioles, glomeruli, and vasa recta is illustrated in Figure 2. RT-PCR products for nNOS and eNOS were identified in all segments studied, but an iNOS product was found only in the arcuate artery. The ß-actin RT-PCR product was used as a control for each reaction. This figure is representative of 4 separate experiments for each segment performed on tissue obtained from 4 separate animals.
|
| Discussion |
|---|
|
|
|---|
The present NOS activity data determined from isolated vessels were normalized to total protein of each vascular segment; total length was not determined, so NOS activity per unit length was not calculated. In addition, there is no way to distinguish between NOS in the endothelium and that in vascular smooth muscle in the different vessels. If, as is commonly assumed, most of the NOS in vessels is found in the endothelium, this method of normalization may skew the data, because there are proportionately more nonendothelial cells, such as vascular smooth muscle cells, in the larger arteries than are found in smaller arteries. To normalize the present NOS enzymatic activity data to the amount of endothelium in the larger cortical vessels, the morphometric data of Smeda et al21 were used to calculate that the endothelium accounted for 3.8%, 5.2%, and 22.7% of total cross-sectional area in the arcuate arteries, interlobular arteries, and afferent arterioles, respectively. If it is assumed that 95% of vasa recta mass is endothelial cells and that the protein content of each component of the vascular wall is proportionate to surface area, the calculated NOS enzymatic activity/endothelial protein in these segments is 37, 90, 186, and 130 pmol/mg endothelial protein per hour in the arcuate artery, interlobular artery, afferent arteriole, and vasa recta, respectively. The present data, when normalized to total tissue protein or total estimated endothelial protein, may therefore indicate the potential capacity of these different vessels to produce and respond to NO. Indeed, it has been previously shown in the isolated perfused split kidney preparation that the afferent arterioles exhibit a greater constriction to N
-nitro-L-arginine7 than do the arcuate or interlobular vessels. The diameter of the efferent arteriole has also been demonstrated to be extremely sensitive to NOS inhibition,8 9 10 although we were unable to obtain sufficient tissue to determine NOS enzymatic activity in efferent arterioles in the present study.
An additional important observation of these studies is the presence of relatively large amounts of total NOS enzymatic activity as well as the mRNA for nNOS and eNOS in the vascular structures of the renal cortex, particularly in the afferent arterioles and glomeruli. A direct comparison of NOS activity measured in renal cortical tissue homogenates and isolated tubules and vessels is not possible because of experimental limitations. It can be inferred from these studies, however, that renal cortical blood vessels possess a level of NO synthetic capacity similar to that found in glomeruli and vasa recta. Because we previously demonstrated that glomeruli and vasa recta have significantly greater total NOS enzymatic capacity than do renal cortical tubular structures, renal cortical blood vessels appear to be relatively enriched in NOS. This conclusion, which is based on biochemical evidence, is consistent with results of large number of functional studies that have demonstrated the effects of NOS in the control of renal vascular resistance. It should also be noted that the vasa recta of the renal medulla has been identified as an additional vascular segment containing large amounts of NOS enzymatic activity. This finding may help explain previous observations in our laboratory demonstrating that systemic administration of the NOS inhibitor L-NAME had a preferential effect on the renal medullary vasculature.22
In the expression studies, RT-PCR products for the constitutive NOS isoforms, nNOS and eNOS, were found in all vessels segments examined, whereas iNOS was detected only in the large arcuate artery. Both eNOS and nNOS have been observed in renal blood vessels in studies from other laboratories,13 14 23 and we previously reported both nNOS and eNOS mRNA in glomeruli and vasa recta.12 iNOS, however, has not been as consistently detected in renal vessels. Whereas one previous study24 did not detect iNOS mRNA in the vasculature of the normal rat, another study15 has indicated that iNOS is present in glomeruli and in arcuate and interlobular arteries. In the present study, iNOS mRNA was detected in the arcuate artery, although only minimal calcium-independent NOS activity was detected in any of the vessels, indicating that iNOS protein is minimally expressed in the renal vasculature. The reason for the differences in iNOS expression found between different studies is unclear.
The potential role of the different NOS isoforms in the control of renal hemodynamics remains to be determined. It is generally accepted that eNOS is the primary source of NO in vessels, although the other isoforms could potentially play a significant role in the regulation of renal vascular resistance. Previous studies have indicated that nNOS may indeed play a role in the control of renal vascular resistance. In 2 different studies,25 26 selective inhibition of nNOS with 7-nitroindazole had no effect on renal vascular resistance in normal rats, although it decreased renal blood flow in furosemide-treated rats or those maintained on a low sodium diet. More recently, chronic 7-nitroindazole administration has been demonstrated to lead to a decrease in renal blood flow in rats maintained on a low or a high sodium diet.27 These pharmacological studies indicate that nNOS participates in the control of renal vascular resistance, although the role of nNOS expressed in the vasculature and that expressed in the macula densa, operating through the tubuloglomerular feedback mechanism,28 is unclear at this time. Other studies29 30 have examined the effects of iNOS inhibition with aminoguanidine. Acute aminoguanidine did not alter whole-kidney blood flow29 or cortical blood flow30 in anesthetized rats, indicating that this isoform has minimal effects on renal vascular resistance. Interestingly, renal medullary blood flow was slightly increased after aminoguanidine administration.30 It is important to note that the renal epithelial segments also contain plentiful amounts of NOS activity12 and that NO produced by different nephron segments may also influence renal vascular resistance.
The changes that occur in NOS enzymatic activity in renal vessels during alterations in dietary sodium intake, changes in hormonal status, and changes during the developmental and maintenance phase of hypertension remain to be determined. Interestingly, changes in tissue NOS activity in hypertensive and normotensive rats are not predicable. Constitutive NOS activity was reduced in the renal medulla of the Dahl salt-sensitive rat made hypertensive by high sodium intake compared with the normotensive Dahl salt-sensitive rat maintained on a low sodium diet.31 In contrast, NOS activity was observed to be increased in the renal medulla of the spontaneously hypertensive rat compared with the Wistar-Kyoto rat.31 It is not presently clear whether these changes occur as a buffering mechanism in response to the elevation in arterial blood pressure, whether they occur because of tissue damage caused by elevated arterial pressure, or whether they are triggered by other factors. In addition, it is not known whether the changes occur in the vasculature or in the renal tubules. Further experiments will be required to begin to understand these changes.
In summary, the present data indicate that a large amount of NOS enzymatic activity is found in the vasa recta, afferent arterioles, and glomeruli, with lesser NOS activity observed in the arcuate and interlobular arteries. The majority of this activity is calcium dependent, indicating that constitutive NOS isoforms produce most of the NO in these vessels. Furthermore, RT-PCR products for nNOS and eNOS were identified in all segments studied. Data from these studies begin to address the potential role of different NOS isoforms in the control of renal segmental vascular resistance.
| Acknowledgments |
|---|
Received September 14, 1999; first decision October 17, 1999; accepted October 29, 1999.
| References |
|---|
|
|
|---|
2. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. J Clin Invest. 1992;89:12481256.
3.
Majid DS, Williams A, Navar LG. Inhibition of nitric oxide synthesis attenuates pressure-induced natriuretic responses in anesthetized dogs. Am J Physiol. 1993;264:F79F87.
4.
Zatz R, DeNucci G. Effects of acute nitric oxide synthase inhibition on rat glomerular microcirculation. Am J Physiol. 1991;261:F360F363.
5.
Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. 1993;264:F212F215.
6.
Deng X, Welch WJ, Wilcox CS. Renal vasodilation with L-arginine: effects of dietary salt. Hypertension. 1995;26:256262.
7.
Imig JD, Roman RJ. Nitric oxide modulates vascular tone in preglomerular arterioles. Hypertension. 1992;19:770774.
8.
Gulbins E, Hoffend J, Zou AP, Dietrich MS, Schlottman K, Cavarape A, Steinhausen M. Endothelin and endothelium-derived relaxing factor control of basal renovascular tone in hydronephrotic rat kidneys. J Physiol (Lond). 1993;469:571582.
9. Edwards RM, Trizna W. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J Am Soc Nephrol. 1993;4:11271132.[Abstract]
10. Ito S, Ren Y. Evidence for the role of nitric oxide in macula densa control of glomerular hemodynamics. J Clin Invest. 1993;92:10931098.
11. Harrison-Bernard LM, Albert DF, Cook AK. Nitric oxide modulation of outer medullary descending vasa recta diameter. FASEB J. 1999;13:A720. Abstract.
12. Wu F, Park F, Cowley AW Jr, Mattson DL. Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J Physiol. 1999;276:F874F881.
13.
Bachman S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol. 1995;268:F885F898.
14.
Ujiie K, Yuen J, Hogarth L, Danziger R, Starr RA. Localization and regulation of endothelial NO synthase mRNA expression in rat kidney. Am J Physiol. 1994;267:F296F302.
15. Mohaupt MG, Elzie JL, Ahn KY, Clapp WL, Wilcox CS, Kone BC. Differential expression and induction of mRNAs encoding two inducible nitric oxide synthases in rat kidney. Kidney Int. 1994;46:653665.[Medline] [Order article via Infotrieve]
16.
Park F, Mattson DL, Roberts LA, Cowley AW Jr. Evidence for the presence of smooth muscle
-actin within pericytes of the renal medulla. Am J Physiol. 1997;273:R1742R1748.
17.
Park F, Mattson DL, Skelton MM, Cowley AW Jr. Localization of the vasopressin V1A and V2 receptors within the renal cortical and medullary circulation. Am J Physiol. 1997;273:R243R251.
18. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991;351:741718.
19. Adachi H, Lida S, Oguchi S, Oshima H, Suzuki H, Nagasaki K, Kawasaki H, Sugimura T, Esumi H. Molecular cloning of a cDNA encoding an inducible calmodulin-dependent nitric oxide synthase from rat liver and its expression in COS-1 cells. Eur J Biochem. 1993;217:3743.[Medline] [Order article via Infotrieve]
20. Briggs JP, Todd-Turla K, Schnermann JB, Killen PD. Approach to the molecular basis of nephron heterogeneity: application of reverse transcription-polymerase chain reaction to dissected tubule segments. Semin Nephrol. 1993;13:212.[Medline] [Order article via Infotrieve]
21. Smeda JS, Lee RMKW, Forrest JB. Structural and reactivity alteration of the renal vasculature of spontaneously hypertensive rats prior to and during established hypertension. Circ Res. 1988;518533.
22.
Nakanishi K, Mattson DL, Cowley AW Jr. Role of renal medullary blood flow in the development of L-NAME hypertension in rats. Am J Physiol. 1995;268:R317R323.
23. Terada Y, Tomita K, Nonoguchi H, Marumo F. Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J Clin Invest. 1992;90:659665.
24.
Ahn KY, Mohaupt MG, Madsen KM, Kone BC. In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. Am J Physiol. 1994;267:F748F757.
25.
Beierwaltes WH. Macula densa stimulation of renin is reversed by selective inhibition of neuronal nitric oxide synthase. Am J Physiol. 1997;272:R1359R1364.
26.
Beierwaltes WH. Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo. Am J Physiol. 1995;269:F134F139.
27. Wilcox CS, Deng X, Welch WJ. NO generation and action during changes in salt intake: roles of nNOS and macula densa. Am J Physiol. 1998;274:R1588R1593.
28.
Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HHW. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A. 1992;89:1199311997.
29. Losonczy G, Bloch JF, Samsell L, Schoenl M, Venuto R, Baylis C. Impact of surgery on nitric oxide in rats: evidence for activation of inducible nitric oxide synthase. Kidney Int. 1997;51:19431949.[Medline] [Order article via Infotrieve]
30.
Mattson DL, Maeda C, Bachman T, Cowley AW Jr. Inducible nitric oxide synthase and blood pressure. Hypertension. 1998;31:1520.
31.
Hayakawa H, Raij L. Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension. 1998;31:266270.
This article has been cited by other articles:
![]() |
C. Du, Q. Guan, H. Diao, Z. Yin, and A. M. Jevnikar Nitric oxide induces apoptosis in renal tubular epithelial cells through activation of caspase-8 Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1044 - F1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Bagnall, P. C. Dent, A. Walkowska, J. Sadowski, and E. J. Johns Nitric oxide inhibition and the impact on renal nerve-mediated antinatriuresis and antidiuresis in the anaesthetized rat J. Physiol., December 15, 2005; 569(3): 849 - 856. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Mattson and C. J. Meister Renal cortical and medullary blood flow responses to L-NAME and ANG II in wild-type, nNOS null mutant, and eNOS null mutant mice Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R991 - R997. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kakoki, H.-S. Kim, W. J. Arendshorst, and D. L. Mattson L-Arginine uptake affects nitric oxide production and blood flow in the renal medulla Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1478 - R1485. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Novak, A. Rajakumar, T. M. Miles, and K. P. Conrad Nitric Oxide Synthase Isoforms in the Rat Kidney During Pregnancy Reproductive Sciences, July 1, 2004; 11(5): 280 - 288. [Abstract] [PDF] |
||||
![]() |
H. C Hercule, M.-H. Wang, and A. O Oyekan Contribution of cytochrome P450 4A isoforms to renal functional response to inhibition of nitric oxide production in the rat J. Physiol., September 15, 2003; 551(3): 971 - 979. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Cowley Jr., T. Mori, D. Mattson, and A.-P. Zou Role of renal NO production in the regulation of medullary blood flow Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2003; 284(6): R1355 - R1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Reckelhoff and J. C. Romero Role of oxidative stress in angiotensin-induced hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R893 - R912. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Pallone, Z. Zhang, and K. Rhinehart Physiology of the renal medullary microcirculation Am J Physiol Renal Physiol, February 1, 2003; 284(2): F253 - F266. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Mattson Importance of the renal medullary circulation in the control of sodium excretion and blood pressure Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2003; 284(1): R13 - R27. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Adler, H. Huang, J. N. Trochu, X. Xu, S. Gupta, and T. H. Hintze Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure Am J Physiol Renal Physiol, November 1, 2001; 281(5): F802 - F809. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kotelevtsev and D. J Webb Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide Cardiovasc Res, August 15, 2001; 51(3): 481 - 488. [Full Text] [PDF] |
||||
![]() |
M. Kakoki, A.-P. Zou, and D. L. Mattson The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R91 - R97. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Govers and T. J. Rabelink Cellular regulation of endothelial nitric oxide synthase Am J Physiol Renal Physiol, February 1, 2001; 280(2): F193 - F206. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |